A detailed history of Walleye Capital LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 7,500 shares of SAGE stock, worth $42,975. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,500
Previous 24,400 69.26%
Holding current value
$42,975
Previous $264,000 79.55%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.02 - $13.08 $647,447 - $1.21 Million
92,229 Added 71.64%
220,973 $1.59 Million
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $660,488 - $1.12 Million
62,428 Added 94.14%
128,744 $1.4 Million
Q1 2024

May 15, 2024

SELL
$18.62 - $26.95 $64,108 - $92,788
-3,443 Reduced 4.94%
66,316 $1.24 Million
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $1.19 Million - $1.55 Million
69,759 New
69,759 $1.51 Million
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $2.22 Million - $3.25 Million
54,561 New
54,561 $2.57 Million
Q2 2022

Aug 08, 2022

BUY
$27.52 - $37.99 $913,636 - $1.26 Million
33,199 New
33,199 $1.07 Million
Q1 2022

May 16, 2022

SELL
$30.71 - $45.71 $2.32 Million - $3.46 Million
-75,679 Closed
0 $0
Q4 2021

Mar 03, 2022

BUY
$37.06 - $47.11 $2.8 Million - $3.57 Million
75,679 New
75,679 $3.22 Million
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $478,647 - $795,901
-18,445 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $482,336 - $1.42 Million
18,445 New
18,445 $530,000
Q4 2019

Feb 14, 2020

SELL
$60.18 - $154.77 $553,595 - $1.42 Million
-9,199 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $1.29 Million - $1.75 Million
9,199 New
9,199 $1.29 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.